The Bell2Bell (B2B) Podcast

Bell2Bell’s latest podcast features Chris Carl, CEO of DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF), an artificial intelligence technology and services company.

Throughout the interview, Carl discussed DigiMax’s history and business model focused on applying AI across various industries and verticals.

“The company was founded four years ago, and we were interested at the time in all things blockchain- and crypto-related,” Carl said. “Four years ago, bitcoin, obviously, was already becoming very popular. The rest of the technology that surrounded the crypto market people weren’t quite sure about, but it definitely looked like it was here to stay, not unlike the internet and the various dotcom strategies going on in the late ‘90s. Everybody had a good sense of where we were headed at a global level but not really individually what applications were going to work best.”

Bell2Bell’s latest podcast features Chris Carl, CEO of DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF), an artificial intelligence technology and services company.

Throughout the interview, Carl discussed DigiMax’s history and business model focused on applying AI across various industries and verticals.

“The company was founded four years ago, and we were interested at the time in all things blockchain- and crypto-related,” Carl said. “Four years ago, bitcoin, obviously, was already becoming very popular. The rest of the technology that surrounded the crypto market people weren’t quite sure about, but it definitely looked like it was here to stay, not unlike the internet and the various dotcom strategies going on in the late ‘90s. Everybody had a good sense of where we were headed at a global level but not really individually what applications were going to work best.”

Bell2Bell’s latest podcast features Hector Bremner, CEO of Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Throughout the interview, Bremner discussed Avricore’s business model and the company’s continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry.

“We’re a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes,” Bremner said. “Our technology is a cloud-based solution that networks these high-quality analyzers from companies like Abbott and is able to then create a testing network in the pharmacy… The patient gets to keep their information, of course… but really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data that can be used for study and research purposes, which is a very, very high demand out there in the sector.”

“My background, funnily enough, was not in health care nor public companies. I was actually in government,” he continued. “Leading into Avricore Health, what got me excited was that we have a disease care system in [Canada], and I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future. We’re really passionate about leading this charge… We’ve got a company that is in great shape and fully funded. We’re growing, and we’ve got a lot of blue sky ahead of us.”

Bremner then discussed some of the recent milestones for Avricore Health.

Bell2Bell’s latest podcast features Hector Bremner, CEO of Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Throughout the interview, Bremner discussed Avricore’s business model and the company’s continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry.

“We’re a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes,” Bremner said. “Our technology is a cloud-based solution that networks these high-quality analyzers from companies like Abbott and is able to then create a testing network in the pharmacy… The patient gets to keep their information, of course… but really, the objective here is to create a global network of pharmacies reporting back real-time information on patient data that can be used for study and research purposes, which is a very, very high demand out there in the sector.”

“My background, funnily enough, was not in health care nor public companies. I was actually in government,” he continued. “Leading into Avricore Health, what got me excited was that we have a disease care system in [Canada], and I’ve always really believed that we need a true health care system that values early detection and screening if we really want to make sure that we’re not only saving lives but saving health care dollars in the future. We’re really passionate about leading this charge… We’ve got a company that is in great shape and fully funded. We’re growing, and we’ve got a lot of blue sky ahead of us.”

Bremner then discussed some of the recent milestones for Avricore Health.

Bell2Bell’s latest podcast features Stephen Jordan, CEO of American Cannabis Partners, a multi-state cannabis company.

Throughout the interview, Jordan discussed the company’s business model and strategic approach to minimizing shareholder risk.

“American Cannabis Partners (“ACP”) is a multi-state operator. We have farms in Northern California, as well as the State of Michigan,” Jordan said. “We have 11 cultivation licenses totaling about 560,000 square foot of canopy space. These are acquired licenses, so it is fully legit. We have a retail license in the State of Michigan, as well. One of the biggest things for us… is assets and safety. That’s one of the hardest things to find in this industry. A lot of people and a lot of companies have products, but they’ve placed themselves in very strenuous liability situations. If they can’t make a product, they no longer have a company. ACP took the opposite direction.”

“We raised capital initially, step-by-step, and we deployed that money into tangible assets – real estate, equipment, things of that nature – just in case some type of bad situation came up or some type of change in a regulatory agency that was no longer a good fit for ACP in that location. We have the ability to liquidate, move and still stay afloat and protect our shareholders,” he continued. “That’s always been a big part for us – assets, assets, assets – and then build the operations out. To this day… we are cash-flow positive, shareholder distribution positive, and we are moving to our third state sometime in the latter half of 2022… preferably on the east coast.”

Jordan then provided some insight into his background in the cannabis sector.

Bell2Bell’s latest podcast features Stephen Jordan, CEO of American Cannabis Partners, a multi-state cannabis company.

Throughout the interview, Jordan discussed the company’s business model and strategic approach to minimizing shareholder risk.

“American Cannabis Partners (“ACP”) is a multi-state operator. We have farms in Northern California, as well as the State of Michigan,” Jordan said. “We have 11 cultivation licenses totaling about 560,000 square foot of canopy space. These are acquired licenses, so it is fully legit. We have a retail license in the State of Michigan, as well. One of the biggest things for us… is assets and safety. That’s one of the hardest things to find in this industry. A lot of people and a lot of companies have products, but they’ve placed themselves in very strenuous liability situations. If they can’t make a product, they no longer have a company. ACP took the opposite direction.”

“We raised capital initially, step-by-step, and we deployed that money into tangible assets – real estate, equipment, things of that nature – just in case some type of bad situation came up or some type of change in a regulatory agency that was no longer a good fit for ACP in that location. We have the ability to liquidate, move and still stay afloat and protect our shareholders,” he continued. “That’s always been a big part for us – assets, assets, assets – and then build the operations out. To this day… we are cash-flow positive, shareholder distribution positive, and we are moving to our third state sometime in the latter half of 2022… preferably on the east coast.”

Jordan then provided some insight into his background in the cannabis sector.

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Bell2Bell’s latest podcast features Brad Rogers, CEO and Executive Chair of Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF). During the briefing, Rogers discussed the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets.

“Red White & Bloom (“RWB”) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately-owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”

Bell2Bell’s latest podcast features Brad Rogers, CEO and Executive Chair of Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF). During the briefing, Rogers discussed the company’s business model and brand strategy spanning multiple rapidly developing U.S. cannabis markets.

“Red White & Bloom (“RWB”) started off as a beachhead in Michigan; it was a state that was not heavily penetrated whatsoever because of the fact that there were no public companies that were able to own a license in that state at the time,” Rogers said. “We came up with a very unique structure to be able to actually take advantage of the regs and enter that state as an investor into a privately-owned company, which we have since gained control over. That was our entry into the market, but what was unique about RWB and RWB brands is the fact that we took a brand strategy to this.”